Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab

Biology of Blood and Marrow Transplantation

Volumn 23, Issue 4, 2017, Pages 635-641

  Marsh, Rebecca A ^a,b   Fukuda, Tsuyoshi ^a,b   Emoto, Chie ^a,b   Neumeier, Lisa ^a,b   Khandelwal, Pooja ^a,b   Chandra, Sharat ^a,b   Teusink Cross, Ashley ^a,b   Vinks, Alexander A ^a,b   Mehta, Parinda A ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Alemtuzumab; Allogeneic hematopoietic cell transplantation; BMT; Bone marrow transplantation; HCT; Pharmacokinetics; Reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; CORTICOSTEROID; CYCLOSPORIN; DIPHENHYDRAMINE; FLUDARABINE; IMMUNOGLOBULIN; MELPHALAN; METHYLPREDNISOLONE; PARACETAMOL; TACROLIMUS; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; VIDARABINE;

ABSOLUTE LYMPHOCYTE COUNT; ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILD; CHRONIC GRANULOMATOUS DISEASE; CLINICAL ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; HEMOPHAGOCYTIC SYNDROME; HUMAN; INFANT; INFLUENZA; IPEX SYNDROME; LYMPHOCYTE COUNT; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHARMACOKINETIC PARAMETERS; PRESCHOOL CHILD; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; RISK REDUCTION; SCHOOL CHILD; SEVERE COMBINED IMMUNODEFICIENCY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; YOUNG ADULT; ANALOGS AND DERIVATIVES; GRAFT VERSUS HOST REACTION; HALF LIFE TIME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PROCEDURES; TRANSPLANTATION CONDITIONING;

ADOLESCENT; ALEMTUZUMAB; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CHILD; CHILD, PRESCHOOL; GRAFT VS HOST DISEASE; HALF-LIFE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LYMPHOCYTE COUNT; MELPHALAN; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 85011320861     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2017.01.071     Document Type: Article

References (22)

1. 1 Rao, K., Amrolia, P.J., Jones, A., et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 105 (2005), 879–885.
2. 2 Shenoy, S., Grossman, W.J., DiPersio, J., et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant 35 (2005), 345–352.
3. 3 Cooper, N., Rao, K., Gilmour, K., et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 107 (2006), 1233–1236.
4. 4 Bhatla, D., Davies, S.M., Shenoy, S., et al. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant 42 (2008), 159–165.
5. 5 Hansen, M.D., Filipovich, A.H., Davies, S.M., et al. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen. Bone Marrow Transplant 41 (2008), 349–353.
6. 6 Marsh, R.A., Rao, M.B., Gefen, A., et al. Experience with alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen. Biol Blood Marrow Transplant 21 (2015), 1460–1470.
7. 7 Gungor, T., Teira, P., Slatter, M., et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 383 (2014), 436–448.
8. 8 Law, J., Cowan, M.J., Dvorak, C.C., et al. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biol Blood Marrow Transplant 18 (2012), 1656–1663.
9. 9 Rebello, P., Cwynarski, K., Varughese, M., Eades, A., Apperley, J.F., Hale, G., Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 3 (2001), 261–267.
10. 10 Mould, D.R., Baumann, A., Kuhlmann, J., et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 64 (2007), 278–291.
11. 11 Patel, K., Parmar, S., Shah, S., et al. Comparison of subcutaneous versus intravenous alemtuzumab for graft-versus-host disease prophylaxis with fludarabine/melphalan-based conditioning in matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant 22 (2016), 456–461.
12. 12 Marsh, R.A., Kim, M.O., Liu, C., et al. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Biol Blood Marrow Transplant 19 (2013), 1625–1631.
13. 13 Chakraverty, R., Orti, G., Roughton, M., et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood 116 (2010), 3080–3088.
14. 14 Lane, J.P., Evans, P.T., Nademi, Z., et al. Low-dose serotherapy improves early immune reconstitution after cord blood transplantation for primary immunodeficiencies. Biol Blood Marrow Transplant 20 (2014), 243–249.
15. 15 Gartner, F., Hieke, S., Finke, J., Bertz, H., Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery. Cytotherapy 15 (2013), 1237–1244.
16. 16 Marsh, R.A., Lane, A., Mehta, P.A., et al. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. Blood 127 (2016), 503–512.
17. 17 Rebello, P., Hale, G., Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods 260 (2002), 285–302.
18. 18 Elsner, J., Hochstetter, R., Spiekermann, K., Kapp, A., Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 88 (1996), 4684–4693.
19. 19 Ambrose, L.R., Morel, A.S., Warrens, A.N., Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Blood 114 (2009), 3052–3055.
20. 20 Hu, Y., Turner, M.J., Shields, J., et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128 (2009), 260–270.
21. 21 Marsh, R.A., Lane, A., Mehta, P.A., et al. Alemtuzumab levels impact acute GVHD, mixed chimerism, & lymphocyte recovery following alemtuzumab, fludarabine & melphalan RIC HCT. Blood 127 (2016), 503–512.
22. 22 Admiraal, R., van Kesteren, C., Jol-van der Zijde, C.M., et al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol 2 (2015), e194–e203.